RapidAI acquires aneurysm management platform developer EndoVantage

TAGS

RapidAI, an AI-based medical imaging company, has acquired EndoVantage, the developer of the Find, Track and Treat cerebral aneurysm management platform for an undisclosed price.

Through the acquisition, RapidAI said that it has continued to grown its scope, from ischemic stroke to hemorrhagic stroke and now to aneurysm.

Last year, the medical imaging company launched Rapid ICH, the next step in AI-powered imaging technology for hemorrhages. Now by acquiring EndoVantage, the company also adds a concentration on aneurysm.

Commenting on RapidAI acquisition of EndoVantage, Don Listwin – CEO of RapidAI said: “By adding the incredible technology developed by EndoVantage to the Rapid platform, we strengthen our position as the global leader in cerebrovascular imaging.

See also  Medtronic’s Symplicity Spyral RDN catheter secures CMS approval for boosted Medicare access

“We can offer hospitals a complete portfolio of products—encompassing ischemic stroke, hemorrhagic stroke, and aneurysm—providing an end-to-end solution that will drive better patient outcomes across the spectrum of cerebrovascular disorders.”

EndoVantage, which began operations at Mayo Clinic and Arizona State University, has developed a computational platform that offers comprehensive cerebral aneurysm management, which automates the complete workflow from initial assessment, growth monitoring, to treatment planning.

See also  Reflow Medical launches DEEPER CORONARY study in coronary in-stent restenosis

The computational platform uses CTA and MRA scans to generate results for helping physicians find and track aneurysm progression. It also makes use of data from 3D rotational angiograms to create detailed 3D models of a patient’s vasculature, thereby enabling presurgical planning for the repair of the aneurysm.

Brian Chong – cofounder of EndoVantage, commenting on RapidAI acquisition of EndoVantage, said: “We are very excited to join the Rapid platform of technology.  EndoVantage covers the spectrum of cerebral aneurysm care from diagnosis through treatment, which helps physicians decide how best to treat their patients.

See also  Classification of the Glycosides and their Properties

“Each patient’s aneurysm is unique, like the patient. Our technology augments a physician’s clinical acumen and experience helping them determine the best plan for each patient.”


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This